Literature DB >> 4048654

Inhibition of smooth muscle cell proliferation and endothelial permeability with flunarizine in vitro and in experimental atheromas.

E Betz, H Hämmerle, T Strohschneider.   

Abstract

Repeated weak electrical stimulations of rabbit carotid artery walls with implanted electrodes cause intimal proliferations of smooth muscle cells (SMC) and lead to fibromuscular plaques beneath the anode. If the animals receive a cholesterol-enriched diet the plaques become typical atheromas. The endothelial lining is maintained. The procedure for the production of an atheroma with 11 +/- 4 layers of SMC lasts 4 weeks. Addition of the calcium antagonist Flunarizine to the food during the stimulation periods inhibits the growth of the plaque. The inhibition is dose-dependent. Whether the drug inhibits atherogenesis by direct action on SMC or via an effect on permeation of macromolecules through the endothelium has been studied by measurement of (1) peroxidase (MW 40,000 dalton) permeability through the stimulated endothelium of the artery and (2) the inhibitory effects of Flunarizine on cultures of arterial SMC. Endothelial permeability increases for some hours after stimulation mainly beneath the anode. Flunarizine inhibits the permeation of peroxidase through the endothelial lining for the most part by its action on intercellular transport. The drug also inhibits the growth of SMC in mass cultures and clone cultures. The inhibition of proliferation is not specific for SMC. Skin fibroblasts obtained from the same animals as the artery smooth muscle cells are also inhibited in mass cultures and clone cultures. From the results it can be concluded that Flunarizine exerts its inhibitory action not only by its effect on the permeation through the endothelial lining but by a combined action on permeability and proliferation of cells in the artery wall.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4048654     DOI: 10.1007/BF01851958

Source DB:  PubMed          Journal:  Res Exp Med (Berl)        ISSN: 0300-9130


  7 in total

Review 1.  Antiatherogenic effects of calcium-channel blockers: possible mechanisms of action.

Authors:  P D Henry
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

2.  Retardation of coronary artery disease in humans by the calcium-channel blocker nifedipine: results of the INTACT study (International Nifedipine Trial on Antiatherosclerotic Therapy).

Authors:  P R Lichtlen; P G Hugenholtz; W Rafflenbeul; H Hecker; S Jost; P Nikutta; J W Deckers
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

3.  Prophylactic endovascular radiotherapy to prevent intimal hyperplasia after stent implantation in femoropopliteal arteries.

Authors:  D Liermann; H D Bottcher; J Kollath; B Schopohl; G Strassmann; E P Strecker; K H Breddin
Journal:  Cardiovasc Intervent Radiol       Date:  1994 Jan-Feb       Impact factor: 2.740

4.  Intimal thickenings of jugular veins after application of a stimulus known to be sclerogenic in arteries.

Authors:  D Kling; V Lindner; J Fingerle; E Betz
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

5.  Effect of cyclandelate on prostacyclin release and cytosolic free calcium concentrations in human endothelial cells.

Authors:  V W van Hinsbergh
Journal:  Drugs       Date:  1987       Impact factor: 9.546

6.  Treatment with an i.v. calcium overload blocker (flunarizine) in acute stroke. A pilot study.

Authors:  P J Hülser; H Bernhart; C Marbach; H H Kornhuber
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1988

7.  Brachytherapy with iridium-192 HDR to prevent from restenosis in peripheral arteries. An update.

Authors:  D Liermann; J Kirchner; R Bauernsachs; B Schopohl; H D Böttcher
Journal:  Herz       Date:  1998-09       Impact factor: 1.443

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.